Report shows growth of the U.S. market for vascular access devices and accessories

Antimicrobial, Safety Devices and PICCs to Drive Market Growth

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for vascular access devices and accessories was valued at just over $3 billion in 2009 and is estimated to reach over $4.6 billion by 2016. The peripherally-inserted-central-catheters (PICCs) and midlines market is expected to see double-digit growth while the dialysis catheter market is expected to grow steadily due to the introduction of antimicrobial technology. The report also states that the antimicrobial central venous catheter (CVC) market was more than double the value of the conventional CVC market in 2009. In addition, growth of the antimicrobial CVC market is exceeding that of the conventional market.

Vascular access devices are used to gain access to a patient's bloodstream through the veins. The devices deliver a range of treatments including fluid infusion, parenteral nutrition, antibiotics, chemotherapy and dialysis. iData's new global series on the Markets for Vascular Access Devices and Accessories 2010 covers implantable-ports, Huber needles, CVCs, dialysis catheters, PICCs, midlines, PIVCs, ultrasound systems, catheter-securement-devices, syringes, needles and needleless connectors.

The report shows that the Needlestick Safety and Prevention Act has promoted sales of higher-priced safety devices, particularly with the advent of needleless connectors. In addition, the recent push to reduce catheter-related bloodstream infections through changes in Medicare and Medicaid reimbursement has been a major driver of growth in the overall vascular access market.

"The drive to reduce infection has been a major source of technological innovation in the vascular access market," says Dr. Kamran Zamanian, CEO of iData. "In an established market such as vascular access, market growth is driven by novel, higher-priced products."